CPC A61K 31/485 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01)] | 7 Claims |
1. A parenteral formulation comprising an aqueous solution comprising about 1.5 mg of nalmefene free base or an equivalent amount of a pharmaceutically acceptable salt thereof and about 0.5% to about 1.0% (w/v) of a parenterally acceptable adjuvant, wherein the formulation provides a mean time to maximum plasma concentration of nalmefene (Tmax) shorter than the mean time to maximum plasma concentration of nalmefene of a comparative formulation without the said adjuvant, post intramuscular or subcutaneous injection to a population of subjects,
wherein the adjuvant is magnesium chloride.
|